Among patients with non-small
cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor
cells (CTCs)
harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.